Home > Search Results

Results: 16

Clear

The aim of this report is to assess the added benefit of crizotinib in patients with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)

Institute for Quality and Efficiency in Health Care (IQWiG).

Version: February 13, 2013

Background In accordance with §35a Social Code Book (SGB) V, the Federal Joint Committee (G-BA) commissioned the Institute for Quality and Efficiency in Health Care (IQWiG) to assess the benefit of the drug crizotinib. The assessment was based on a dossier compiled by the pharmaceutical company (hereinafter referred to as “the company”). The dossier was sent to IQWiG on 21 December 2015.

Institute for Quality and Efficiency in Health Care (IQWiG).

Version: March 30, 2016

On 15 November 2012 the Federal Joint Committee (G-BA) commissioned the Institute for Quality and Efficiency in Health Care (IQWiG) to conduct a benefit assessment of crizotinib pursuant to § 35a Social Code Book V (Commission No. A12-15). The assessment was made on the basis of a dossier of the pharmaceutical company (hereinafter abbreviated to “the company”). On 15 February 2013 the G-BA published IQWiG’s dossier assessment of 13 February 2013 for comment.

Institute for Quality and Efficiency in Health Care (IQWiG).

Version: April 15, 2013

Background In accordance with §35a Social Code Book (SGB) V, the Federal Joint Committee (G-BA) commissioned the Institute for Quality and Efficiency in Health Care (IQWiG) to assess the benefit of the drug ceritinib. The assessment was based on a dossier compiled by the pharmaceutical company (hereinafter referred to as “the company”). The dossier was sent to IQWiG on 30 June 2015.

Institute for Quality and Efficiency in Health Care (IQWiG).

Version: September 29, 2015

Expert-reviewed information summary about the treatment of childhood non-Hodgkin lymphoma.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: August 3, 2017

Expert-reviewed information summary about the treatment of childhood soft tissue sarcomas.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: August 9, 2017

Expert-reviewed information summary about the genomics of childhood cancer. The summary describes the molecular subtypes for specific pediatric cancers and their associated clinical characteristics, the recurring genomic alterations that characterize each subtype at diagnosis or relapse, and the therapeutic and prognostic significance of the genomic alterations. The genomic alterations associated with brain tumors, kidney tumors, leukemias, lymphomas, sarcomas, and other cancers are discussed.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: October 18, 2017

The study found no strong evidence that any one epidermal growth factor receptor mutation test had greater accuracy than any other test when used to identify previously untreated adults with locally advanced or metastatic non-small-cell lung cancer.

Health Technology Assessment - NIHR Journals Library.

Version: May 2014

This study of erlotinib [Tarceva®, Roche (UK) Ltd] and gefitinib (IRESSA®, AstraZeneca) for treating non-small cell lung cancer that has progressed following prior chemotherapy found that a lack of clinical data for distinct patient populations limited the conclusions of the assessment. The study authors recommended that future trials should distinguish between patients with epidermal growth factor mutation-positive and epidermal growth factor mutation-negative (EGFR M–) disease. The Assessment Group’s cost-effectiveness analysis comparing erlotinib with docetaxel inpatients whose disease has progressed favoured the use of docetaxel in a mainly EGFR M– patient population.

Health Technology Assessment - NIHR Journals Library.

Version: June 2015

Expert-reviewed information summary about the treatment of non-small cell lung cancer.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: March 31, 2017

Expert-reviewed information summary about the treatment of childhood neuroblastoma.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: September 28, 2017

Lung cancer is the leading cause of cancer death in both men and women in the United States, and male Veterans seeking care at VA hospitals have a much higher age-specific incidence of lung cancer than males in the general population. The personal and economic significance of lung cancer has led to a vast research endeavor to try and identify new and more effective treatments. Most patients with lung cancer are diagnosed when the cancer is already advanced (stage IIIB or IV), and they are no longer candidates for surgical resection. Small cell lung cancer and non-small cell lung cancer (NSCLC) are different diseases in terms of treatment. Until recently, all therapies for advanced NSCLC were based on their cytotoxic properties. In the last few years, several novel agents aimed at specific molecular targets have been developed. This review was requested to evaluate the current evidence on the effectiveness and cost-effectiveness of treatments for advanced lung cancer.

Evidence-based Synthesis Program - Department of Veterans Affairs (US).

Version: October 2012

The Coverage and Analysis Group at the Centers for Medicare and Medicaid Services (CMS) requested that the Technology Assessment Program (TAP) of the Agency for Healthcare Research and Quality (AHRQ) conduct an update of genetic tests for cancer conditions that were identified since the 2011 horizon scan report on Genetic Testing for Cancer. AHRQ assigned this project to the Tufts Medical Center Evidence-based Practice Center (Contract Number: HHSA 290 2007 10055 I, Task Order #11).

Technology Assessment Report - Agency for Healthcare Research and Quality (US).

Version: July 19, 2013

The study found that independent Evidence Review Groups frequently conduct exploratory analyses to test or improve the economic evaluations submitted to the National Institute for Health and Care Excellence (NICE) by companies as part of the single technology appraisal process. These analyses often influence the recommendations produced by NICE Technology Appraisal Committees.

Health Technology Assessment - NIHR Journals Library.

Version: April 2016

Study provides a comprehensive framework of information for three subpopulations of patients with non-small cell lung cancer that clinicians can refer to as they attempt to balance patient factors, available treatments, treatment costs and adverse events in their daily decision-making.

Health Technology Assessment - NIHR Journals Library.

Version: July 2013

Technologies collectively called omics enable simultaneous measurement of an enormous number of biomolecules; for example, genomics investigates thousands of DNA sequences, and proteomics examines large numbers of proteins. Scientists are using these technologies to develop innovative tests to detect disease and to predict a patient's likelihood of responding to specific drugs. Following a recent case involving premature use of omics-based tests in cancer clinical trials at Duke University, the NCI requested that the IOM establish a committee to recommend ways to strengthen omics-based test development and evaluation. This report identifies best practices to enhance development, evaluation, and translation of omics-based tests while simultaneously reinforcing steps to ensure that these tests are appropriately assessed for scientific validity before they are used to guide patient treatment in clinical trials.

National Academies Press (US).

Version: March 23, 2012

Systematic Reviews in PubMed

See all (42)...

Systematic Review Methods in PubMed

See all (1)...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...